A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Name: A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Published: 2025
License: Public Domain

Actimed Therapeutics Ltd · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

obesity semaglutide

obesity, muscle loss, semaglutide, s-pindolol, glp-1, glucagon-like peptide-1 receptor agonist, lean body mass, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Related documents